$7.34 Million is the total value of Yu Fan's 6 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 20.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ABGI | ABG ACQUISITION CORP I | $4,978,000 | +1.3% | 501,300 | 0.0% | 67.82% | -10.8% | |
New | APEXIGEN INC | $1,085,000 | – | 401,757 | +100.0% | 14.78% | – | |
SONENDO INC | $586,000 | -37.8% | 547,945 | 0.0% | 7.98% | -45.2% | ||
CSTL | CASTLE BIOSCIENCES INC | $537,000 | +18.8% | 20,592 | 0.0% | 7.32% | +4.6% | |
PRENETICS GLOBAL LTDclass a ord | $95,000 | -5.9% | 25,000 | 0.0% | 1.29% | -17.2% | ||
AGLE | AEGLEA BIOTHERAPEUTICS INC | $59,000 | +3.5% | 112,044 | 0.0% | 0.80% | -8.8% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
CASTLE BIOSCIENCES INC | 12 | Q3 2023 | 24.7% |
ABG ACQUISITION CORP I | 8 | Q4 2022 | 83.9% |
SONENDO INC | 8 | Q3 2023 | 60.4% |
PRENETICS GLOBAL LTD | 6 | Q3 2023 | 1.9% |
DIFFUSION PHARMACEUTICALS IN | 6 | Q1 2022 | 0.8% |
CASTLE BIOSCIENCES INC | 5 | Q2 2023 | 25.8% |
APEXIGEN INC | 4 | Q2 2023 | 14.8% |
ATEA PHARMACEUTICALS INC | 3 | Q2 2021 | 61.3% |
PULMONX CORP | 2 | Q1 2021 | 36.2% |
SAGIMET BIOSCIENCES INC | 1 | Q3 2023 | 35.7% |
View Yu Fan's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Pulmonx Corp | February 11, 2022 | 31,903 | 0.1% |
View Yu Fan's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
4 | 2023-06-21 |
13F-HR | 2023-05-15 |
4 | 2023-03-15 |
4 | 2023-03-03 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
View Yu Fan's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.